Background: KEYNOTE 024 study established single-agent pembrolizumab as the preferred first-line therapy for patients with metastatic NSCLC with a TPS score >50% , without sensitizing EGFR or ALK mutations. However, this is a minor subset of metastatic NSCLC patients. Modulation of immune response through PD-1 inhibition may be enhanced by the potential…
Keep reading with a 7-day free trial
Subscribe to Hematology Oncology Snippets to keep reading this post and get 7 days of free access to the full post archives.